Estradiol is converted to catechol estrogens via 2-and 4-hydroxylation by cytochrome P450 enzymes. 4-Hydroxyestradiol elicits biological activities distinct from estradiol, most notably an oxidant stress response induced by free radicals generated by metabolic redox cycling reactions. In this study, we have examined 2-and 4-hydroxylation of estradiol by microsomes ofhuman uterine myometrium and of associated myomata. In all eight cases studied, estradiol 4-hydroxylation by myoma has been substantially elevated relative to surrounding myometrial tissue (minimum, 2-fold; mean, 5-fold). Estradiol 2-hydroxylation in myomata occurs at much lower rates than 4-hydroxylation (ratio of 4-hydroxyestradiol/2-hydroxyestradiol, 7.9 + 1.4) and does not significantly differ from rates in surrounding myometrial tissue. Rates of myometrial 2-hydroxylation of estradiol were also not significantly different from values in patients without myomata. We have used various inhibitors to establish that 4-hydroxylation is catalyzed by a completely different cytochrome P450 than 2-hydroxylation. In myoma, at-naphthoflavone and a set of ethynyl polycyclic hydrocarbon inhibitors (5 ,uM) each inhibited 4-hydroxylation more efficiently (up to 90%o) than 2-hydroxylation (up to 40%o), indicating >10-fold differences in Kj (<0.5 ,uM vs. >5 ,uM). These activities were clearly distinguished from the selective 2-hydroxylation of estradiol in placenta by aromatase reported previously (low K., inhibition by Fadrozole hydrochloride or ICI D1033).
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4-Hydroxylation was also selectively inhibited relative to 2-hydroxylation by antibodies raised against cytochrome P450 IBN (rat) (53 vs. 17%). These data indicate that specific 4-hydroxylation of estradiol in human uterine tissues is catalyzed by a form(s) ofcytochrome P450 related to P450 IBi, which contribute(s) little to 2-hydroxylation. This enzyme(s) is therefore a marker for uterine myomata and may play a role in the etiology of the tumor.
2-Hydroxylation of estradiol (E2) is the primary metabolic oxidation of this hormone in most mammalian species (1, 2) . In human liver, this metabolic oxidation is catalyzed mainly by cytochrome P450 IIIA and, to a lesser extent, IA family enzymes (2, 3) . Cytochrome P450 IA enzymes have also been identified as estrogen 2-hydroxylases in extrahepatic tissues and in MCF-7 human breast cancer cells (2, 4, 5) . In addition, aromatase has been reported to catalyze the 2-hydroxylation of E2 in placenta (6) . Aromatic hydroxylations of estrogens by these enzymes mainly result in 2-hydroxylated catechol estrogens (CE) accompanied by small amounts of 4-hydroxylated estrogens (<20% of total CE metabolites) (1, 2) . Therefore, 4-hydroxyestradiol (4-OH-E2) has been considered as an unimportant by-product of 2-hydroxyestradiol (2-OH-E2) formation because rates of its formation by microsomal preparations are low relative to total CE formation (1, 2) and also because urinary concentrations of 4-hydroxylated estrogens are much lower than those of 2-hydroxylated metabolites (7, 8) . In contrast, in microsomes of MCF-7 cells induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin, a specific E2 4-hydroxylase activity distinct from the more common 2-hydroxylase activity has been detected by selective inhibition of the latter activity with anti-rat P450 IA IgG (4). Moreover, a specific E2 4-hydroxylase activity has been identified in rat pituitary and mouse uterus, in which it represents the almost exclusive form of CE formation (9, 10) , and in hamster kidney, in which it has been unmasked by inhibitors of E2 2-hydroxylase activity, such as by Fadrozole hydrochloride (11) . A physiological function of this estrogen metabolite and of the form(s) of cytochrome P450 catalyzing its formation is not known.
E2 induces malignant cancers in hamster kidney (12) , mouse uterus (13) , and hyperplasia in rat pituitary (14) . The expression of a specific E2 4-hydroxylase activity in these three rodent organs, in which estrogens induce tumors, and also in a human breast cancer cell line has been taken as evidence for a role of 4-OH-E2 formation in the development of benign and/or malignant E2-induced tumors (11, 15) . This hypothesis was developed because CE, including 4-OH-E2, are capable of undergoing metabolic redox cycling between the catechol (hydroquinone) and corresponding quinone forms (16) . Such redox cycling is a mechanism to generate potentially mutagenic free radicals (17) . 4 -OH-E2 may also contribute to carcinogenesis by acting as a mitogen because it is known to be a long-acting estrogen (18) . In line with this hypothesis, 4-OH-E2 was found to be as carcinogenic as E2 in the hamster kidney tumor model (19) .
In this study, 2-and 4-hydroxylase activities have been assayed in microsomes of human uterine myoma and surrounding myometrial tissue to examine the hypothesis that 4-OH-E2 formation serves as a marker of uterine myomata and plays a role in tumor development. Values were compared to enzyme activities in myometrial microsomes of patients without apparent myomata. For the identification of enzymes catalyzing 2-and 4-hydroxylation, several inhibitors of specific forms of cytochrome P450 were investigated. We also examined CE formation by microsomes of human placenta for the validation Abbreviations: E2, 1713-estradiol; 2-OH-E2 and 4-OH-E2, 2-hydroxyestradiol and 4-hydroxyestradiol, respectively; CE, catechol estrogen(s). 9221 of the assays. In our studies, we identified 4-hydroxylation of E2 in human tissues as a specific metabolic pathway distinct from the more common 2-hydroxylation. (26) .
MATERIALS AND METHODS

Chemicals
Microsome Preparation. Human uterine tissues after excision were immediately transferred to the surgical pathology laboratory, sectioned, placed in ice-cold homogenization buffer (1.14% KCl/10 mM EDTA, pH 7.5), and homogenized with a Tekmar (Cincinnati) Ultra-Turrax homogenizer. Microsomes were prepared by differential centrifugation according to the method of Dignam and Strobel (27) . Microsomal pellets were resuspended in storage buffer (0.25 M sucrose/10 mM EDTA, pH 7.5) and frozen in aliquots at -80°C until used.
Protein concentrations were determined by the method of Bradford using bovine serum albumin as standard (28) .
Portions of placentae from healthy women were obtained within 1 hr of term deliveries. The tissues were rinsed repeatedly in ice-cold homogenization buffer to remove excess blood. Microsomes were prepared as described above (27) .
Microsome-Mediated CE Formation. A validated direct product isolation assay was used to determine rates of CE formation. The assay method and its validation have been described in detail (29) (Fig. 1) .
a-Naphthoflavone, an inhibitor of cytochrome P450 IAl/ IA2 (20) , inhibited 2-hydroxylase activity in myoma microsomes by 43% and potently inhibited 4-hydroxylase activity by almost 90% ( 2-hydroxylation but inhibited 4-hydroxylation by 38% and 52%, respectively. At higher concentrations, these inhibitors inhibited 2-hydroxylation of E2 by "30% and 4-hydroxylation of E2 by up to 80% (data not shown). 1-Ethynylpyrene and 2-, 3-, and 9-ethynylphenanthrene, known to affect activities of both cytochromes P450 IAl and IB1 enzymes (24), inhibited E2 2-hydroxylase activity in myoma microsomes by 29-38% and 4-hydroxylase by up to 89%.
A partial but specific inhibition of 4-hydroxylase activity of myoma microsomes was obtained with an antibody raised against cytochrome P450 IB1. At a concentration of 1 mg of cytochrome P450 IB1 antibody per mg of microsomal protein, the rate of 4-hydroxylation of 10 ,uM E2 was decreased by 34% from the control value, whereas 2-hydroxylation was not affected (Fig. 2) . At an antibody concentration of 2 mg per mg of microsomal protein, the rate of E2 4-hydroxylation was inhibited by 53%, whereas that of 2-hydroxylation was decreased by 17% (Fig. 2) .
In summary, 4-hydroxylation of E2 is the almost exclusive form of CE formation by microsomes of human myoma. Approximately 50% of this 4-hydroxylase activity is catalyzed by form(s) of cytochrome P450 IB1 recognized by an antibody raised against a rodent form of this enzyme. The small amount of 2-hydroxylase activity in myoma microsomes is affected by specific inhibitors of cytochromes P450 IA enzymes.
Uterine Myometrium. The rates of 2-hydroxylation of 5 ,M E2 by 15 myometrium microsomes were not different from those of myoma microsomes (Table 1) . However, mean rates of 4-hydroxylation of 5 ,uM E2 by myometrium microsomes (0.08 ± 0.08 pmol/mg of protein per min) were significantly lower than those of myoma microsomes (P < 0.01). The lower rates of 4-hydroxylation by myometrium compared to myoma microsomes are also reflected by significantly lower ratios of rates of 4-OH-E2/2-OH-E2 formation. Variations were much larger in rates of 4-hydroxylation than 2-hydroxylation. For instance, in two myometrium microsomes (patients 1 and 3), a predominant 4-hydroxylation of E2 was evident, whereas in one other sample (patient 13), 2-and 4-hydroxylation rates were comparable (Table 1) .
A kinetic analysis of 2-hydroxylation of E2 by three myo- (0.5 ± 0.2 and 1.2 + 0.6, respectively).
As with myoma microsomes, a-naphthoflavone partially inhibited 2-hydroxylation in myometrium (57%) while reducing 4-hydroxylase activity to <20% of controls ( (30) .
DISCUSSION
Our data identify a specific estrogen 4-hydroxylase activity in human tissues. In uterine myoma, 4-hydroxylation of E2 is the predominant form of CE formation and occurs at rates 5-fold higher than in surrounding myometrium. Large variations in ratios of 4-OH-E2/2-OH-E2 formation seen in uterine myometrium are due to variations in 4-hydroxylase activity, whereas 2-hydroxylase activity varies less and is comparable to that in myoma. This predominance of 4-hydroxylation of E2 contrasts with CE formation by microsomes of human liver (2, 3, 5) or placenta (Table 1 and ref. 30) , which express mainly 2-hydroxylase activity. The conversion of E2 predominantly to 2-OH-E2 has been reported to be catalyzed by cytochrome P450 IIIA and aromatase enzymes, respectively (2, 3, 5, 6) . In incubations with hepatic or placental enzymes, 4-OH-E2 is only a minor by-product of the more common formation of 2-OH-E2.
The enzyme(s) catalyzing this specific 4-hydroxylation of E2 may be identical or related to cytochrome P450 IB1 {previ-ously identified as EF [for embryo fibroblast (33)]}, a special class of cytochromes P450 previously detected in embryo and uterine endometrial fibroblast cells of mouse and fibroblasts of mammary glands of rats (26, (31) (32) (33) . This hypothesis is supported by the specific inhibition of '50% of 4-hydroxylation of E2 by an antibody raised against a rodent form of this enzyme. This antibody also inhibits 4-hydroxylation of E2 in human breast cancer cells such as MCF-7 and T47D, which also express cytochrome P450 IB1 (34) . Moreover, inhibition studies by a series of ethynylated hydrocarbon inhibitors suggest that 2-hydroxylation and 4-hydroxylation of E2 in both myoma and myometrium are catalyzed by distinct enzyme systems.
2-Hydroxylation of E2 by myoma or myometrium microsomes likely is catalyzed by cytochrome P450 IA and other isozymes. CE formation by aromatase, reported previously for placenta microsomes (6), does not play a role in uterine tissues. This fact has been confirmed here by the inhibition studies using Fadrozole hydrochloride or ICI D1033, which inhibit placental but not uterine conversion of E2 to catechol metabolites.
The biological role of 4-hydroxylation of E2 by cytochrome P450 IB1 is unknown. 4-OH-E2 has been postulated to mediate blastocyst implantation based on physiological studies in the mouse uterus (10) . Whether formation of this metabolite is the main function of this form(s) of cytochrome P450 remains to be ascertained. 4-OH-E2 has also been postulated to participate in E2-induced tumor formation in hamster kidney (11, 15) . This hypothesis is based on the metabolic redox cycling between hydroquinone (CE) and quinone intermediates of CE, including 4-OH-E2, which may generate potentially mutagenic free radicals (16, 17) and on the decreased dissociation of 4-OH-E2 from the estrogen receptor complex, which makes this catechol metabolite a long-acting estrogen (18) . Consistent with this hypothesis, a specific E2 4-hydroxylase activity in animals has been identified in hamster kidney (11) , mouse uterus (10) , and rat pituitary (11) , which all serve as animal models of estrogen-induced tumorigenesis. In human tissues, an E2 4-hydroxylase distinct from the more common 2-hydroxylase has been detected in MCF-7 cells, a breast cancer cell line (4, 34) , and in benign and malignant neoplastic mammary tissue (35) . In our study, a specific E2 4-hydroxylase activity has been demonstrated in human uterine myoma and, with lower activity, in surrounding myometrium. The presence of elevated cellular 4-hydroxylase activity in myometrium may predispose to myoma formation. Elevated formation of 4-OH-E2 in precursor cells could mediate benign tumor formation consistent with a postulated role of this estrogen metabolite in the formation of benign or malignant tumors in rodent models. The postulated development of benign or malignant uterine tumors in women with high E2 4-hydroxylase activity requires further studies.
In summary, a specific E2 4-hydroxylase activity has been identified in human uterine myoma and, at lower activity, in uterine myometrium. Elevated 4-OH-E2 formation in myometrial precursor cells is postulated to mediate benign tumor growth consistent with a role of this estrogen metabolite in estrogen-induced rodent tumors.
